Genome Editing Market Size, Share, Opportunities, And Trends By Technology (CRISPR, TALEN, ZFN, Others), By Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), By End-User (Academic & Government Research Institutes, Biotechnology & Pharmaceutical Companies, Contract Research Organizations), And By Geography – Forecast From 2025 To 2030

Genome Editing Market Size:

The genome editing market is expected to grow from USD 4.087 billion in 2025 to USD 8.018 billion in 2030, at a CAGR of 14.43%.

Genome editing is a method of making changes in a living organism’s DNA and is used for improving crop yields, diagnosing and treating diseases, and for research purposes. The research and development in genome editing have been increasing worldwide as it is being used in the agriculture and healthcare sectors. Also, investments in genome editing have been rising as the technique is being seen to have the potential to solve various problems, which is anticipated to surge the market growth during the forecast period. Furthermore, the support of various governments worldwide for the use of genome editing to improve crop yields is another prominent factor expected to drive the genome editing market. Moreover, the growing cases of cancer and other genetic disorders are surging the need for effective treatment and consequently leading to the market growth of genome editing.

Genome Editing Market Drivers:

• Growing cases of cancer and other genetic disorders

The cases of cancer and other genetic disorders have been increasing globally. The growing interest in genome editing for the treatment of cancer and several genetic disorders is anticipated to propel the growth of the genome editing market during the forecast period. NIH researchers have recently, in January 2021, found and recognized a new genetic disorder called linkage-specific-deubiquitylation-deficiency-induced embryonic defects syndrome (LINKED) that causes delays in development and hinders the proper formation of the heart, facial features, and brain. Such identifications of new genetic disorders also contribute to the rising cases of genetic disorders. Furthermore, cancer cases have been proliferating. According to data from the International Agency for Research on Cancer (IARC), the number of cancer cases in the United Kingdom (England and Wales) has increased from 138,577 in 2010 to 156,444 in 2017 for males and from 130,674 in 2010 to 149,239 in 2017 for females. As per IARC, the number of cancer cases in Europe is projected to jump from 4.398 million in 2020 to 5.323 million in 2040, witnessing an increase of around 21%. In North America, the cases of cancer are projected to reach 3.525 million in 2040, increasing from 2.557 million in 2020, and growing by nearly 38%. This is expected to have a positive impact on the genome editing market in the coming years, owing to an increasing need for better cancer treatments.

• Rising investments and research in genome editing

In September 2021, the UK government announced its plans to support gene editing in agriculture to support the country’s farmers in growing better and more productive crops. The government is making research and development easier. It also aims to make the necessary measures for genome-edited products to reach the safely and responsibly to the market. Furthermore, the government of China is backing the use of CRISPR, a genome-editing technique, to improve the food supply in the country. In 2017, a state-owned company in China named ChemChina acquired Syngenta, a Switzerland-based agribusiness company working with CRISPR with an extensive research and development team. China spent $43 billion on the deal, which is the largest amount ever spent by China on buying a foreign company. The investments in genome editing are expected to grow further in the coming years, along with rising research and development, and are anticipated to boost the genome editing market growth during the forecast period.

Genome Editing Market Geographical Outlook:

• North America to dominate the global market

Geographically, the North American region is anticipated to hold a significant market share owing to the large investments being made in the region in the field of genome editing. The Asia Pacific region is anticipated to witness substantial growth due to the surging cases of genetic disorders and cancer, along with higher spending on healthcare and research. As per the data from IARC, the number of cancer cases in Asia is projected to grow by more than 59%. Furthermore, the use of CRISPR has been increasing substantially in China, which is further expected to contribute to market growth in the Asia Pacific.

Genome Editing Market Segmentation

• By Technology Type
  • CRISPR
  • TALEN
  • ZFN
  • Others
• By Application
  • Cell Line Engineering
  • Animal Genetic Engineering
  • Plant Genetic Engineering
  • Others
• By End-User
  • Academic & Research Institutes
  • Biotechnology & Pharmaceutical Company
  • Contract Research Organization
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • UK
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

---

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. GENOME EDITING MARKET BY TECHNOLOGY TYPE

5.1. Introduction

5.2. CRISPR

5.3. TALEN

5.4. ZFN

5.5. Others

6. GENOME EDITING MARKET BY APPLICATION

6.1. Introduction

6.2. Cell Line Engineering

6.3. Animal Genetic Engineering

6.4. Plant Genetic Engineering

7. GENOME EDITING MARKET BY END-USER

7.1. Introduction

7.2. Academic & Research Institutes

7.3. Biotechnology & Pharmaceutical Company

7.4. Contract Research Organization

8. GENOME EDITING MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. Germany

8.4.2. France

8.4.3. United Kingdom

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. India

8.6.3. Japan

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Thermo Fisher Scientific Inc.

10.2. Merck & Co., Inc.

10.3. Horizon Discovery Group plc

10.4. GenScript

10.5. Sangamo Therapeutics, Inc.

10.6. Danaher Corporation

10.7. Lonza Group AG

10.8. BEX Co., LTD.

10.9. OriGene Technologies, Inc.

10.10. CRISPR Therapeutics

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

Thermo Fisher Scientific Inc.

Merck & Co., Inc.

Horizon Discovery Group plc

GenScript

Sangamo Therapeutics, Inc.

Danaher Corporation

Lonza Group AG

BEX Co., LTD.

OriGene Technologies, Inc.

CRISPR Therapeutics